ABX: Lone public life settlement firm, 8× forward earnings

Pass #15 in this channel's daily small-cap screen. Abacus Global Management (NYSE: ABX) clears all four hard filters and trades at 8.16× forward earnings — less than half the life insurance sector median — while posting 86% TTM revenue growth, a 15% free cash flow yield, and an operating cash flow swing of $153M year-over-year in Q1 2026. The business occupies a structural monopoly: it is the only publicly traded life settlement company in the United States. The bear case is equally structural: a 76-page short-seller report alleges the portfolio is systematically overvalued using related-party life expectancy data, and 13.86% of the float is short. This note lays out both sides with the numbers.

Current price: $8.73 (June 8, 2026). Market cap: $838.84M. 1

Hard filter check

Hard screening metrics — ABX (TTM through Q1 2026)

All four filters passed as of June 8, 2026 — dual-source verified

Market cap

$0.00−91.6%vs $10B cap

TTM revenue growth

0.0+56.1%above 30% floor

PEG ratio

0−14.0%vs 1.0 ceiling

TTM operating cash flow

$0.00+153000000.0%swing vs Q1 2025

正在加载统计卡片…

PEG cross-check: StockAnalysis reports 0.86 (using ~9.5% forward EPS growth estimate); Finviz reports 0.48 (using a 15.79% five-year EPS growth estimate). Both are below 1.0. The more conservative StockAnalysis figure is used here. TTM revenue growth: 86.13% (StockAnalysis) / 82.95% (Finviz) — both far exceed the 30% floor. 1 2

What Abacus does

Abacus Global Management, headquartered in Orlando, FL, is the only publicly traded life settlement company in the United States, listed on the NYSE under ticker ABX since December 2025 (formerly Abacus Life Inc. on Nasdaq under ABL). The company buys life insurance policies from seniors — typically at 6–8× the cash surrender value — and manages those policies as alternative assets for institutional investors. 3

The business runs across four verticals:

Life Solutions — originates life settlement assets, purchasing policies and supplying them across the platform; $50.6M of Q1 2026 revenue
Intel — proprietary mortality analytics and data technology, described by management as "the competitive moat"; $0.36M in Q1 2026 (still small but key to underwriting edge)
Asset Group — manages longevity-based funds and ETFs for institutional investors; $8.5M in Q1 2026, with AUM up ~4× YoY to ~$1B
Wealth Advisors — connects ~30,000 financial advisors with longevity-based financial strategies

Since 2004, Abacus has acquired policies with over $10 billion in face value. The company has 78 institutional partners and is licensed in 49 states. 3 With 326 employees generating $768,370 in revenue per employee, the model is capital-light at the operating level — though the balance sheet carries $341M in debt used to fund policy acquisitions. 1

CEO Jay Jackson describes the structural pitch: "Longevity-based assets continue attracting institutional demand because they are structurally uncorrelated to credit and equity cycles." 4 The market context supports that framing: Conning's 2025 Life Settlements Strategic Study estimates the annual gross market potential at $224 billion, with actual annual transaction volumes at $4.6 billion — Abacus participated in roughly 20% of the 3,181 secondary market transactions recorded in 2024. 5

One important note from the short-seller record: Morpheus Research contends Abacus spent most of its history as a fee-based originator for third-party buyers, only beginning to acquire policies for its own balance sheet in June 2021 — casting doubt on the "20-year track record" cited in sell-side research. Abacus disputes this characterization. 6

Five quarters of revenue

正在加载图表…

The sequential pattern warrants a word of context: Q1 2026's $59.4M was down 17.4% from Q4 2025's $71.9M, but Q1 is structurally the weakest quarter — Q1 2025 showed the same seasonal pattern. Year-over-year, Q1 2026 grew 34.6% from $44.1M — consistent with the company's operating trajectory. 7

The full-year picture is more striking. Annual revenue: FY2022 $44.7M → FY2023 $66.4M (+48.5%) → FY2024 $111.9M (+68.6%) → FY2025 $235.2M (+110.2%) → TTM $250.5M (+86.1%). 7 Growth includes both organic originations — Q1 2026 origination capital deployment hit $163.6M, up 30% YoY — and inorganic contributions from the AccuQuote acquisition (October 2025) and the Dynasty Financial Partners minority stake (August 2025). 8

FY2025 full-year results: revenue $235.2M (+110% YoY), adjusted net income $85.7M (+84%), adjusted EBITDA $132.6M (+115%), originations capital deployment $580.8M (+53%), 1,310 policies originated (+26%). CEO Jay Jackson: "We closed the year by delivering another strong quarter, achieving eleven consecutive quarters beating consensus." 9

Q1 2026 added $20.1M in adjusted net income (+17% YoY), $32.7M in adjusted EBITDA (+33%), and an operating cash flow of $91.7M — a swing of +$153M from the -$61.6M recorded in Q1 2025. Management raised full-year 2026 adjusted net income guidance to $100M–$106M (from $96M–$104M), implying adjusted EPS of approximately $1.00–$1.05. 8

Valuation: cheap on forward earnings, premium on trailing

The trailing P/E of 23.05 looks expensive relative to life insurance peers. The forward P/E of 8.16 looks cheap relative to almost everything. The gap exists because FY2025 GAAP net income ($36.5M) was compressed by $38.8M in interest expense and a one-time negative OCF year — while FY2026 consensus EPS of ~$1.01–$1.15 reflects the earnings inflection already underway. 1

	ABX	UNM	CNO	GL	LNC	GNW
Forward P/E	8.16×	~9×	~10×	~10×	~5×	~11×
Trailing P/E	23.05×	18.85×	19.27×	10.96×	4.02×	16.38×
P/S	3.35×	~0.7×	~0.8×	~1.5×	~0.4×	~0.5×
EV/EBITDA	9.87×	—	—	—	—	—
P/B	2.01×	~1.5×	~1.2×	~2.0×	~0.6×	~0.8×
PEG	0.86	n/a	n/a	n/a	n/a	n/a
Gross margin	88.8%	~20–30%	~20–30%	~25%	~15%	~20%

Peer identities: UNM (Unum Group, disability and life insurer), CNO (CNO Financial Group, life/health insurer for middle-income), GL (Globe Life, direct-to-consumer life insurer), LNC (Lincoln National, annuities and group benefits), GNW (Genworth Financial, mortgage insurance and long-term care). 10

The P/S premium (3.35× vs. the 0.5–1.5× range for traditional life insurers) is justified by ABX's 88.8% gross margin — roughly 3–4× the gross margin of a conventional insurer, which reflects the nature of the business: policies are assets, not policyholder obligations. The FCF yield of 15.08% ($126.8M TTM FCF on $838M market cap) is the standout metric. 1

One caveat on FY2025 earnings quality: StockTitan's analysis found that FY2025 net income of $36.5M was accompanied by operating cash flow of -$25.7M — a -0.70× earnings quality ratio, signaling that FY2025 profits were largely accrual-driven. Q1 2026 OCF of $91.7M represents a decisive improvement, and TTM OCF of $127.6M now comfortably exceeds net income. 11

Balance sheet

The balance sheet improved materially from FY2025 to Q1 2026. Current ratio jumped from 0.47 to 1.91 after $115.9M in short-term debt was reclassified or repaid. Total liabilities dropped from $478.7M to $407.2M. 12

The remaining concerns are structural rather than acute:

Total debt: $341.3M (TTM), carrying a 9.875% coupon on the ABXL senior notes due 2028 — a high cost of debt
Net debt: -$304.1M (-$3.17 per share)
Interest coverage: 2.48× — adequate but thin; a ~40% drop in EBITDA would leave interest uncovered
Goodwill: $252.8M (30.5% of total assets $829.8M), from the AccuQuote, Dynasty, and prior acquisitions
Tangible book value: $1.08 per share — the gap between $4.29 book value per share and $1.08 tangible reflects acquired intangibles

The Altman Z-Score sits between 1.48 (StockTitan, using SEC-filed FY2025 data) and 1.70 (StockAnalysis) — below the 1.81 distress threshold. The primary drag is negative retained earnings (-$41.6M accumulated deficit) and the low working capital ratio that characterized FY2025. The strongest component is market cap-to-total liabilities at 1.78×. 11 12

Growth catalysts

Manning & Napier strategic alliance. On May 27, 2026, Abacus closed a $53M minority equity investment in Manning & Napier (founded 1970, ~$18B AUM). The three-pillar Strategic Alliance Agreement covers: (1) joint lifespan-based financial planning products combining Abacus's LifeARC actuarial data with Manning & Napier's planning capabilities, (2) distribution of Abacus ETFs and longevity funds to Manning & Napier's investor base, and (3) bi-directional lead generation — Abacus routes ~10,000 monthly life settlement origination leads to Manning & Napier's wealth advisory platform. Greg Holden, Manning & Napier's President of Wealth Management: "By pairing Manning & Napier's 55 years of investment and planning experience with Abacus's proprietary longevity insights, we will be able to deliver a more complete financial plan." 13

AUM scaling. Longevity Income Fund AUM grew approximately 4× YoY to ~$1B in Q1 2026. Total gross AUM reached ~$3.6B on $378M in gross capital inflows. CEO Jackson outlined a five-year path to ~$450M in adjusted EBITDA at scale, with recurring revenue targeted at 70% of the total mix — compared to the current mix heavily weighted toward transaction revenue. 9

Institutional demand tailwind. The life settlement market sits in a secular growth window: aging demographics (target market is policyholders over 65 with policies over $100K), low correlation to public markets, and $224B in estimated annual gross market potential against $4.6B in current annual transactions — a penetration rate under 2%. 5 Abacus's NYSE listing (December 2025) and Russell 2000/3000 inclusion (September 2025) extended its institutional investor reach.

Second securitization. Management indicated on the Q1 2026 call that a second securitization is "advancing on schedule." The first securitization contributed to the elevated Q4 2025 portfolio turnover ratio of 2.6×. A completed second deal would further validate institutional demand for life settlement paper as a distinct asset class. 8

Key risks

The Morpheus short thesis (SEVERITY: HIGH — unresolved). In June 2025, Morpheus Research published a 76-page report alleging Abacus systematically overvalues its life settlement portfolio. The core claim: Lapetus Solutions — Abacus's primary life expectancy (LE) provider, in which Abacus holds a minority interest — produces shorter life expectancy estimates than peers, inflating policy valuations and reported income. Shorter LEs → higher present values → higher reported assets. If Lapetus LE estimates are overstated by a sustained margin, the $392.8M policy portfolio on Abacus's balance sheet could be materially overstated; a 10–20% markdown would reduce the $422.6M equity base by 9–19%. 6

Morpheus also alleges: (a) actual portfolio turnover is ~20% quarterly (implying ~1.3-year average holding period), versus Abacus's stated 1.5–2.0× annual target; (b) policies may be "round-tripped" through affiliated funds to mask true asset values — pointing to $141.4M in policies "sold" in Q2 2025 that may have gone to entities Abacus controls; (c) the independent actuarial validation by Lewis & Ellis is compromised, as Lewis & Ellis was named in a separate life settlement fund lawsuit. Abacus denied all allegations and threatened legal action; all four covering analysts (all with banking relationships) dismissed the report within hours of publication. The short interest has remained elevated at 13.86% of float — 11.23 days to cover — more than a year after the report. 6

Altman Z-Score in distress zone (SEVERITY: MEDIUM). At 1.48–1.70, all three scoring sources place ABX below the 1.81 distress threshold. The score is suppressed by negative retained earnings, high leverage, and significant goodwill relative to total assets. Q1 2026 showed the current ratio recovering to 1.91, but the accumulated deficit of $34.5M and 9.875% debt cost keep the structural score depressed. 11

Related-party revenue concentration (SEVERITY: MEDIUM). In Q1 2026, related-party revenues totaled $24.0M — roughly 40% of total Q1 revenue ($7.4M from asset management, $16.6M from life solutions). The loss of major institutional fund partners would directly reduce reported revenue. 8

Dilution outpacing buybacks (SEVERITY: LOW–MEDIUM). Shares outstanding increased 26.17% YoY — driven by the November 2024 follow-on offering of 12.5M shares, stock-based compensation, and acquisition issuances. The $20M share repurchase program (with $14.5M deployed in Q1 2026) has not offset the dilution. Shareholder yield stands at -23.89% when net dilution is subtracted from the 2.29% dividend yield. 1

Level-3 fair value opacity (SEVERITY: MEDIUM, structural). Abacus's policy portfolio is carried at Level 3 fair value — unobservable inputs, meaning investors cannot independently verify valuations. The reliance on Lapetus (a related party) for life expectancy inputs creates an inherent conflict. GWG Holdings, a life settlement company that went bankrupt in 2022 with $2B+ in policies, is the industry cautionary tale. 6

Price action, ownership, and upcoming catalysts

Elderly hands counting coins — the core asset in life settlement is time on a policy — Life settlements convert senior policyholders' unwanted coverage into cash — the asset class Abacus buys and manages. 5

ABX trades at $8.73, up 46.00% over the past 52 weeks. The 52-week range is $4.60–$10.53; the stock sits 16.9% below the annual high. Year-to-date: +2.40%. The 50-day moving average is $8.92 (price is 2.1% below); the 200-day is $7.76 (price is 12.5% above). RSI (14-day): 45.51 — neutral, not oversold. Beta (5-year): 0.09 — nearly uncorrelated to broader market moves, consistent with the "structurally uncorrelated" asset description. Average 20-day volume: ~544,000–632,000 shares. 1 2

Insider and institutional ownership. Insider ownership stands at 55.08% — the four co-founders (Jay Jackson, Sean McNealy, Matthew Ganovsky, Scott Kirby) occupy the top leadership positions and collectively control the majority of shares. Institutional ownership is 28.34%. The public float is 43.09M shares — thin relative to market cap, which amplifies both upside and short-squeeze potential. Insiders conducted small routine sales at $8.38 in February 2026; no open-market purchases on record at current levels. 1 3

Analyst consensus. Five analysts cover ABX, all with Buy ratings. Average 12-month price target: $13.10 (49% upside from $8.73). Range: $11.00 (Piper Sandler, downgraded to Neutral March 13, 2026) to $16.00 (B. Riley, Buy). Three-year forward revenue growth forecast: 12.98%; three-year EPS growth forecast: 9.53% — analysts expect significant deceleration from the current 86% TTM pace. One caveat: per Morpheus Research, all four major covering analysts (B. Riley, Piper Sandler, TD Cowen, Northland) co-managed Abacus equity and debt offerings, generating banking fees — a conflict of interest that retail investors should discount. Analyst targets are directional, not precise; the $13.10 average requires the forward earnings inflection to materialize. 14

Upcoming catalysts:

Q2 2026 earnings (expected ~August 6–7, 2026): Guidance is $24M–$26M adjusted net income, $0.24–$0.26 adjusted EPS. This will be the first quarter to include any Manning & Napier-related contributions. The OCF trajectory is the key variable — two consecutive quarters of positive OCF would substantially reduce the FY2025 earnings-quality concern.
Second securitization close: Referenced as "on schedule" in the Q1 call; timing not specified but expected H2 2026. A completed deal would provide price discovery on life settlement paper from institutional fixed-income buyers.
ABX named to TIME's World's Growth Leaders 2026 (June 5, 2026): A reputational catalyst with potential to expand retail and institutional investor awareness.

Bottom line

ABX passes all four hard filters with margin: TTM revenue +86.13%, PEG 0.86, TTM OCF $127.6M, market cap $838.84M. 1 At 8.16× forward earnings and a 15% FCF yield, the stock is cheap by any conventional metric for a company growing revenue at this pace — and the 55% insider ownership means management's wealth is tied to the outcome.

The bear case is not trivially dismissed. Thirteen-plus percent short interest a year after the Morpheus report means a cohort of informed sellers still believes the portfolio valuation is unreliable. The Level-3 policy portfolio, the Lapetus related-party LE inputs, the round-tripping allegations, and the Altman Z-Score below the distress threshold are not noise — they are the price of entry into a genuinely novel asset class with limited comparables. GWG Holdings is the reference failure for anyone inclined to dismiss the short thesis outright.

The practical framework: investors willing to accept that the Q1 2026 OCF swing ($91.7M, a $153M reversal) and the raised guidance represent a real improvement in cash generation are looking at an 8× forward earner with a 15% FCF yield, no comparables, and 49% upside to analyst consensus. Investors who believe the portfolio valuation is unreliable should avoid, regardless of the price. The two camps are unlikely to converge before Q2 2026 earnings provide another data point.

Three things to monitor:

Q2 2026 OCF (August earnings): A second consecutive quarter of strong positive OCF would confirm the FY2025 reversal was not seasonal. Target: $60M+ to remain on the $100M–$106M adjusted net income guidance path.
Short interest trend: If short interest begins declining meaningfully from 13.86% of float, it signals the bear thesis is losing institutional conviction.
Lapetus disclosure: Any further regulatory or legal development related to the Morpheus allegations — particularly regarding Lapetus life expectancy methodology — would be a material catalyst in either direction.

Cover image: elderly hands with coins, Pixabay (Frantisek_Krejci, CC0).